Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

13.05USD
25 May 2017
Change (% chg)

$0.27 (+2.11%)
Prev Close
$12.78
Open
$12.88
Day's High
$13.18
Day's Low
$12.85
Volume
314,067
Avg. Vol
2,228,507
52-wk High
$24.91
52-wk Low
$9.70

Latest Key Developments (Source: Significant Developments)

Endo reports Q1 GAAP loss per share $0.74
Tuesday, 9 May 2017 06:30am EDT 

May 9 (Reuters) - Endo International PLC : :Endo reports first-quarter 2017 financial results.Q1 adjusted earnings per share $1.23 from continuing operations.Q1 GAAP loss per share $0.74 from continuing operations.Q1 revenue $1.038 billion versus I/B/E/S view $1.02 billion.Q1 earnings per share view $1.10 -- Thomson Reuters I/B/E/S.Endo International PLC sees 2017 total revenues to be between $3.45 billion to $3.60 billion.Endo International PLC sees 2017 reported diluted gaap loss per share from continuing operations to be between $0.80 and $0.50.Endo International PLC sees 2017 adjusted diluted eps from continuing operations to be between $3.45 to $3.75.Endo International PLC - divestiture of its south african subsidiary, Litha Healthcare Group, to Acino Pharma AG is expected to close in Q2 of 2017.Endo International PLC - during first-quarter 2017, company recorded total combined pre-tax, non-cash impairment charges of $204 million.FY2017 earnings per share view $3.61 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.54 billion -- Thomson Reuters I/B/E/S.Endo International PLC - in April 2017, endo refinanced its $3.7 billion existing credit agreement.Endo International - recorded Q1 2017 restructuring cash charges of $15 million related to its restructuring program.  Full Article

Endo International priced $300 million aggregate amount of 5.875% senior secured notes
Wednesday, 12 Apr 2017 09:36pm EDT 

Endo International Plc : Endo International Plc announces pricing of private offering of senior secured notes .Endo International-cos subsidiaries, priced $300 million aggregate amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount.  Full Article

Endo International priced $300 million aggregate amount of 5.875% senior secured notes
Wednesday, 12 Apr 2017 07:20pm EDT 

Endo International Plc : Endo International Plc announces pricing of private offering of senior secured notes .Endo International-cos subsidiaries, priced $300 million aggregate amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount.  Full Article

Endo International announces proposed private offering of senior secured notes
Monday, 10 Apr 2017 01:27pm EDT 

Endo International Plc : Endo International PLC announces proposed private offering of senior secured notes .Intends to use net proceeds to repay all outstanding loans, all other obligations under its existing credit facilities.  Full Article

Endo International sees total Q1 2017 revenues between $1,015 mln - $1,035 mln
Monday, 10 Apr 2017 08:02am EDT 

Endo International Plc : Endo International Plc - currently estimates total Q1 2017 revenues to be between $1,015 million and $1,035 million . Endo International Plc - Endo currently expects its Q1 2017 EBITDA from continuing operations to be between $440 million and $460 million .Q1 revenue view $1.02 billion -- Thomson Reuters I/B/E/S.  Full Article

Endo International Plc announces plan to refinance existing credit agreement
Wednesday, 5 Apr 2017 07:30am EDT 

Endo International Plc : Endo International Plc announces plan to refinance existing credit agreement . Endo International Plc - new credit facilities are expected to be guaranteed by Endo and certain of its subsidiaries . Endo International Plc - transactions, if completed, would not be expected to materially change Endo's total debt . Endo International Plc - intends to use proceeds, together with net proceeds of other debt (which may be secured), to repay all outstanding loans and other obligations .Endo International Plc - intends to use net proceeds of new credit facilities, together with net proceeds of other debt to repay all outstanding loans.  Full Article

Endo International former CEO Rajiv De Silva's FY 2016 compensation $19.2 mln vs $10.9 mln in FY 2015
Wednesday, 22 Mar 2017 04:14pm EDT 

Endo International Plc :Endo international plc - former ceo rajiv de silva's fy 2016 total compensation was $19.2 million versus $10.9 million in fy 2015 - sec filing.  Full Article

FDA staff: Difficult to assess impact of Opana ER’s reformulation on overall abuse of the drug
Thursday, 9 Mar 2017 09:33am EST 

Endo International Plc : FDA staff: postmarketing data suggests opana er reformulation likely reduced nasal abuse rates, but data limitations makes it hard to determine magnitude of effect . FDA staff: postmarketing data indicate an increase in opana er injection abuse rates over the study period .FDA staff: the data are difficult to interpret with regard to the impact of opana er’s reformulation on overall abuse of the drug (via any route)..  Full Article

Endo CEO says expects to launch about 20 products, generate about $100 million from those products in 2017
Tuesday, 28 Feb 2017 10:53am EST 

Endo International Plc : Endo CEO says newly-launched generic drugs Quetiapine & Ezetimibe generated close to $300 million in Q4 sales . Endo CEO: 2017 generic sales to decline in high single to low double-digit percentage range, partially offset by growth in sterile injectables & new launches . Endo CEO: sales of flagship branded product Xiaflex, driven primarily by double-digit demand growth, particularly in Peyronie's disease . Endo CEO: expects 2017 specialty business to grow in the high single digits, driven primarily by expected high single to low double-digit growth for Xiaflex . Endo CEO: portion of the cost savings from restructuring of co's pain business will be redeployed in 2017 to support core franchises, including Xiaflex . Endo CEO: says co has started due diligence process for the potential sale of somar business . Endo CFO: Q1 operating expenses expected to be largely in line with Q4 2016, due to the timing of certain expenses & recently announced restructuring initiatives . Endo CEO: "It will take some time to successfully address the challenges that endo faces today and it will take time to reposition endo for long-term success." . Endo CEO: "At this time we're not going to be able to guide beyond where we are in 2017" . Endo CEO says expects to launch about 20 products and generate about $100 million from those products in 2017.  Full Article

Endo Q4 adjusted earnings $1.77/shr from continuing operations
Tuesday, 28 Feb 2017 06:30am EST 

Endo International Plc : Endo International Plc - announces divestiture of Litha Healthcare Group for $100 million . Endo reports fourth-quarter and full-year 2016 financial results . Q4 adjusted earnings per share $1.77 from continuing operations . Q4 GAAP loss per share $14.96 from continuing operations . Sees FY 2017 revenue $3.45 billion to $3.6 billion . Q4 revenue $1.242 billion versus I/B/E/S view $1.16 billion . Q4 earnings per share view $1.63 -- Thomson Reuters I/B/E/S . Endo International Plc sees 2017 adjusted EBITDA from $1.50 billion to $1.58 billion . FY 2017 revenue view $3.83 billion -- Thomson Reuters I/B/E/S . Endo International Plc sees 2017 adjusted diluted EPS from continuing operations to be between $3.45 to $3.75 . FY 2017 earnings per share view $4.27 -- Thomson Reuters I/B/E/S . Endo International Plc sees 2017 reported diluted GAAP EPS from continuing operations to be between $0.04 and $0.34 .Endo International - reports $3.5 billion of asset impairment charges in fourth-quarter 2016 associated with write-down of goodwill and intangible assets.  Full Article

More From Around the Web